Literature DB >> 10780856

Expression of osteoclast differentiation signals by stromal elements of giant cell tumors.

G J Atkins1, D R Haynes, S E Graves, A Evdokiou, S Hay, S Bouralexis, D M Findlay.   

Abstract

The mechanisms by which primary tumors of the bone cause bone destruction have not been elucidated. Unlike most other lytic bone tumors, osteoclastomas, otherwise known as giant cell tumors (GCT), contain osteoclast-like cells within the tumor stroma. A new member of the TNF-ligand superfamily member, osteoclast differentiation factor (ODF/OPGL/RANKL/TRANCE), was recently identified. ODF was shown to directly stimulate osteoclastogenesis, in the presence of M-CSF. In this study, the expression of ODF was examined in a number of tumor samples associated with bone lysis in vivo. In addition, we investigated expression of the ODF receptor on osteoclast precursors, RANK, as well as the ODF inhibitor osteoprotegerin (OPG), and another TNF-ligand superfamily member, TRAIL, previously shown to abrogate the inhibitory effects of OPG. We report here the novel finding that GCT stromal cells contain abundant ODF mRNA, whereas the giant cell population exclusively expresses RANK mRNA. These results are consistent with the osteoclast-mediated bone destruction by these tumors. We also report the expression of OPG and TRAIL mRNA in GCT samples. A comparison with other lytic and nonlytic tumors of bone showed that GCT express more ODF and TRAIL mRNA relative to OPG mRNA. In addition, GCT were found to express a number of cytokines previously reported to play central roles in osteoclastogenesis, namely, IL-1, -6, -11, -17, as well as TNF-alpha. Importantly, GCT were also found to express high levels of M-CSF mRNA, a cytokine shown to be an essential cofactor of ODF, and a survival factor for mature and developing osteoclasts. Furthermore, expression of these molecules by stromal cells isolated from GCT continued in vitro. Thus GCT constitutively express all of the signals that are currently understood to be necessary for the differentiation of osteoclasts from precursor cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780856     DOI: 10.1359/jbmr.2000.15.4.640

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  45 in total

1.  Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis.

Authors:  Jeske J Smink; Per-Ulf Tunn; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2011-11-10       Impact factor: 4.599

Review 2.  Giant cell tumor of bone.

Authors:  Alan W Yasko
Journal:  Curr Oncol Rep       Date:  2002-11       Impact factor: 5.075

3.  Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts.

Authors:  Tao Ma; Kavitha Sadashivaiah; Nandakumar Madayiputhiya; Meenakshi A Chellaiah
Journal:  J Biol Chem       Date:  2010-07-22       Impact factor: 5.157

Review 4.  Giant cell tumour of bone: morphological, biological and histogenetical aspects.

Authors:  Mathias Werner
Journal:  Int Orthop       Date:  2006-09-30       Impact factor: 3.075

5.  Intratibial injection of patient-derived tumor cells from giant cell tumor of bone elicits osteolytic reaction in nude mouse.

Authors:  Leqin Xu; Zhipeng Wu; Zhenhua Zhou; Xinghai Yang; Jianru Xiao
Journal:  Oncol Lett       Date:  2018-07-16       Impact factor: 2.967

6.  Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression.

Authors:  Siddhant U Jain; Sima Khazaei; Dylan M Marchione; Stefan M Lundgren; Xiaoshi Wang; Daniel N Weinberg; Shriya Deshmukh; Nikoleta Juretic; Chao Lu; C David Allis; Benjamin A Garcia; Nada Jabado; Peter W Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-16       Impact factor: 11.205

Review 7.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

8.  A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases.

Authors:  Ira J Miller; Alan Blank; Suellen M Yin; Allison McNickle; Robert Gray; Steven Gitelis
Journal:  Diagn Pathol       Date:  2010-09-22       Impact factor: 2.644

9.  Giant cell tumor of bone: a neoplasm or a reactive condition?

Authors:  Anwar Ul Haque; Ambreen Moatasim
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 10.  RANKL/RANK/OPG: key therapeutic target in bone oncology.

Authors:  Kosei Ando; Kanji Mori; Francoise Rédini; Dominique Heymann
Journal:  Curr Drug Discov Technol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.